The rescheduling of cannabis could pave the way for the development and distribution of over-the-counter (OTC) cannabis products. This possibility would mark a significant shift in how cannabis is accessed and used, with implications for consumer safety, product standardization, and regulatory oversight.
OTC cannabis products would require clear labeling, dosage instructions, and quality control to ensure consumer safety. This transition would also necessitate a robust regulatory framework to oversee the production and distribution of these products, ensuring they meet health and safety standards.
The impact of OTC cannabis products on public health, consumer behavior, and the existing medical cannabis industry would be substantial. The Food and Drug Administration (FDA) provides guidance on OTC drug regulations, which could be adapted for cannabis products, available at FDA.gov.
